CRSP – crispr therapeutics ag - common shares (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

CRSP

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

2/17

09:09 am

crsp

CRISPR Therapeutics (NASDAQ:CRSP) had its "underweight" rating reaffirmed by analysts at Morgan Stanley.

Low Report

CRISPR Therapeutics (NASDAQ:CRSP) had its "underweight" rating reaffirmed by analysts at Morgan Stanley.

Report

2/17

09:09 am

crsp

CRISPR Therapeutics (NASDAQ:CRSP) had its "underweight" rating reaffirmed by analysts at Morgan Stanley.

Low Report

CRISPR Therapeutics (NASDAQ:CRSP) had its "underweight" rating reaffirmed by analysts at Morgan Stanley.

Report

2/17

08:18 am

crsp

Rating for CRSP

Low Report

Rating for CRSP

Report

2/16

08:05 am

crsp

CRISPR Therapeutics (NASDAQ:CRSP) had its "buy" rating reaffirmed by analysts at Citigroup Inc..

Low Report

CRISPR Therapeutics (NASDAQ:CRSP) had its "buy" rating reaffirmed by analysts at Citigroup Inc..

Report

2/13

10:59 am

crsp

Rating for CRSP

Low Report

Rating for CRSP

Report

2/13

10:16 am

crsp

CRISPR Therapeutics (NASDAQ:CRSP) had its "outperform" rating reaffirmed by analysts at Evercore ISI.

Low Report

CRISPR Therapeutics (NASDAQ:CRSP) had its "outperform" rating reaffirmed by analysts at Evercore ISI.

Report

2/13

10:16 am

crsp

CRISPR Therapeutics (NASDAQ:CRSP) had its "outperform" rating reaffirmed by analysts at Evercore ISI.

Low Report

CRISPR Therapeutics (NASDAQ:CRSP) had its "outperform" rating reaffirmed by analysts at Evercore ISI.

Report

2/13

06:31 am

crsp

Rating for CRSP

High Report

Rating for CRSP

Report

2/13

06:31 am

crsp

Rating for CRSP

High Report

Rating for CRSP

Report

1/30

07:17 am

crsp

CRISPR Therapeutics (NASDAQ:CRSP) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..

Medium Report

CRISPR Therapeutics (NASDAQ:CRSP) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..

Report

12/23

09:03 am

crsp

CRISPR Therapeutics (NASDAQ:CRSP) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $80.00 price target on the stock.

Low Report

CRISPR Therapeutics (NASDAQ:CRSP) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $80.00 price target on the stock.

Report

12/23

09:02 am

crsp

Rating for CRSP

Low Report

Rating for CRSP

Report

12/23

09:02 am

crsp

Rating for CRSP

Low Report

Rating for CRSP

Report

11/26

09:31 am

crsp

Rating for CRSP

Low Report

Rating for CRSP

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.